Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations.
arteriovenous malformation
bleomycin
lymphatic malformation
pharmacokinetics
vascular anomalies
vascular malformation
venous malformation
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
25
02
2022
received:
15
12
2021
accepted:
21
03
2022
pubmed:
30
4
2022
medline:
28
6
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
Bleomycin, a chemotherapy agent that inhibits synthesis of DNA, has been increasingly utilized in sclerotherapy for patients with vascular malformations. A serious long-term risk of intravenous bleomycin is dose-dependent interstitial pneumonitis. Little is known about absorption and circulating levels of bleomycin when used in sclerotherapy for patients with vascular malformations. This is an Institutional Review Board (IRB)-approved prospective study on patients receiving bleomycin sclerotherapy in the management of vascular malformations. Depending on the type of vascular malformation, bleomycin was administered either in the lumen or interstitial space of the involved lesion. A bleomycin assay measured serum bleomycin plasma concentrations versus time at seven intervals following treatment. Pharmacokinetic parameters were obtained for each participant and included peak plasma concentration (C
Substances chimiques
Sclerosing Solutions
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29733Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Horbach SER, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, van der Horst CMAM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137(1):244-256. https://doi.org/10.1097/PRS.0000000000001924
Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65(2):81-94. https://doi.org/10.1007/BF02034932
Mack JM, Richter GT, Becton D, Salem O, Hill SEM, Crary SE. Short-term side effects and patient-reported outcomes of bleomycin sclerotherapy in vascular malformations. Pediatr Blood Cancer. 2018;65(6):e27008. https://doi.org/10.1002/pbc.27008
Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617-624. https://doi.org/10.1378/chest.120.2.617
Andler W. [Pulmonary side effects of bleomycin therapy]. Klin Padiatr. 1984;196(1):47-48. https://doi.org/10.1055/s-2007-1025573
Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881-901. https://doi.org/10.1378/chest.10-2133
De A, Guryev I, LaRiviere A, et al. Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. Pediatr Blood Cancer. 2014;61(9):1679-1684. https://doi.org/10.1002/pbc.25098
Armenian SH, Landier W, Francisco L, et al. Long-term pulmonary function in survivors of childhood cancer. J Clin Oncol. 2015;33(14):1592-1600. https://doi.org/10.1200/JCO.2014.59.8318
Alberts DS, Chen HS, Mayersohn M, Perrier D, Moon TE, Gross JF. Bleomycin pharmacokinetics in man. II. Intracavitary administration. Cancer Chemother Pharmacol. 1979;2(2):127-132. https://doi.org/10.1007/BF00254085.
Broughton A, Strong JE, Holoye PY, Bedrossian CW. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer. 1977;40(6):2772-2778. https://doi.org/10.1002/1097-0142(197712)40:6<2772::aid-cncr2820400603>3.0.co;2-1
Groselj A, Krzan M, Kosjek T, Bosnjak M, Sersa G, Cemazar M. Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. Cancer Chemother Pharmacol. 2016;77(5):939-947. https://doi.org/10.1007/s00280-016-3004-z
Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet. 1987;12(3):168-213. https://doi.org/10.2165/00003088-198712030-00002
Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE. Bleomycin disposition in children with cancer. Clin Pharmacol Ther. 1983;33(5):668-673. https://doi.org/10.1038/clpt.1983.91
Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin's disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys. 1989;16(3):679-685. https://doi.org/10.1016/0360-3016(89)90485-9
Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol. 1999;21(2):115-122. https://doi.org/10.1097/00043426-199903000-00007